NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

NeuroPace, Inc. (Nasdaq: NPCE), a pioneering medical device company dedicated to improving the lives of individuals with epilepsy, has announced the date for its third quarter 2025 financial results report. The report will be released after market close on Tuesday, November 4, 2025. Following the announcement, NeuroPace's management will host a conference call to discuss the financial results, which will start at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Investors interested in the conference call can listen via a live webcast accessible at [this link](https://events.q4inc.com/attendee/831496029). For those who wish to participate by phone, the dial-in number is +1 (800) 715-9871, with the Conference ID 8467256 for reference. The conference call will also be archived on NeuroPace's investor relations website, where it will be available for replay for at least 90 days following the event.

NeuroPace is based in Mountain View, California, and it leads the industry with its innovative Responsive Neurostimulation (RNS) System—the first commercially available brain-responsive platform designed specifically to deliver real-time, personalized treatment at the source of seizures. This cutting-edge technology aims to enhance the standard of care for patients who struggle with drug-resistant epilepsy. Moreover, the RNS System presents promising avenues for personalized care and enhanced outcomes for a broader array of brain disorders, addressing the needs of a large patient population affected by these conditions.

For further inquiries, investors can contact Scott Schaper, Head of Investor Relations, via email at sschaper@neuropace.com or investors@neuropace.com.

As NeuroPace, Inc. prepares to report its third-quarter financial results for 2025 on November 4th, investors should closely monitor several key indicators that could influence the company’s stock performance. The company continues to be a leader in developing innovative medical devices for individuals living with epilepsy, specifically through its RNS System, which offers personalized treatment aimed at mitigating the impact of drug-resistant seizures. This unique value proposition positions NeuroPace favorably in a growing market.

In anticipation of the earnings report, investors should review NeuroPace's recent performance metrics, including revenue growth, traction in new patient acquisitions, and the expansion of reimbursement policies for its RNS System. Analysts will likely assess the year-over-year growth rates and the company’s ability to maintain its competitive edge amidst a rapidly evolving healthcare environment.

Moreover, key trends in the healthcare sector, particularly in neuromodulation technologies and epilepsy treatments, can provide insight into NeuroPace’s market potential. As awareness and acceptance of innovative therapies continue to rise, NeuroPace could see increased demand driven by expanding indications for its devices.

It is also essential for investors to tune into the conference call following the earnings report. Management’s commentary will shed light on operational efficiencies, strategic partnerships, and future guidance that could have profound implications for the company’s growth trajectory. Additionally, analysts attending the call may provide updated forecasts based on management insights.

Overall, while the upcoming earnings report will be critical for assessing NeuroPace’s current position, investors should keep an eye on industry trends and regulatory developments that may impact the company’s future prospects. Remaining informed and active in these discussions can enhance investment decision-making surrounding NeuroPace's growth potential as the company navigates the complex healthcare landscape.